Price
$1.21
Increased by +6.14%
Dollar Volume
300.35 K
ADR%
11.34
Earnings Report Date (estimate)
Mar 8, 23 (-0.4)
Market Cap.
58.15 M
Shares Float
28.24 M
Shares Outstanding
48.06 M
Beta
1.75
Price / Earnings
-0.30
BPR
76.03
20D Range
0.70 1.24
50D Range
0.70 1.25
200D Range
0.50 2.22
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.40
Increased by +63.30%
-0.48
Increased by +16.67%
Aug 12, 22 -0.96
Increased by +3.03%
-0.78
Decreased by -23.08%
May 12, 22 -0.88
Increased by +12.00%
-0.83
Decreased by -6.02%
Mar 10, 22 -1.04
Increased by +1.89%
-1.25
Increased by +16.80%
Nov 12, 21 -1.09
Increased by +18.05%
-1.16
Increased by +6.03%
Aug 12, 21 -0.99
Increased by +22.05%
-1.13
Increased by +12.39%
May 11, 21 -1.00
Decreased by -69.49%
-1.01
Increased by +0.99%
Mar 18, 21 -1.06
Increased by +32.48%
-1.25
Increased by +15.20%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-19.10 M
Increased by +32.79%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-25.86 M
Decreased by -0.11%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-23.12 M
Increased by +4.38%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-27.16 M
Decreased by -14.65%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-28.42 M
Increased by +4.78%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-25.83 M
Increased by +7.95%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-24.18 M
Decreased by -95.48%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-23.69 M
Decreased by -34.34%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.